Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Manoj T. Duraisingh, Ph.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
Wadham College, University of Oxford, Oxford, United KingdomB.A.Hons1993
London School of Hygiene and Tropical Medicine, London, United KingdomM.Sc.1994
London School of Hygiene and Tropical Medicine, London, United KingdomPhD1999

Overview
Malaria remains one of the most serious infectious diseases of humans with an estimated 500 million new infections and approximately 2 million deaths each year. We are interested in understanding the processes that underlie the pathogenesis of human malarial disease at the cellular and molecular level.

Plasmodium falciparum is a protozoan parasite, which multiplies exponentially in red blood cells (erythrocytes) in the course of its life-cycle, resulting in the clinical symptoms associated with severe malaria. We have developed transfection-based molecular and cell biological tools for the functional analysis of genes that may be involved in the initiation and progression of disease. We are also developing forward genetic screens for the identification of new molecules associated with virulence. These advances have coincided with the complete sequencing of the P. falciparum genome, which provides us with a blueprint to unravel the unique biology and genetics of this organism.

In the laboratory, we focus on the molecular basis of erythrocyte invasion by P. falciparum. To initiate a blood-stage infection, invasive forms (known as merozoites) recognize multiple receptors on the surface of the erythrocyte, after which they signal to initiate a cascade of intracellular events to complete the invasion process. We are interested in elucidating the functions of the molecules involved in this complex process. Such an understanding is a prerequisite for the rational design of vaccines directed against this life-cycle stage.

Also of interest is the regulation of antigenic variation in P. falciparum-infected erythrocytes. Following invasion, P. falciparum remodels the infected erythrocyte with the export of various proteins to the erythrocyte surface. Amongst these is a family of molecules, encoded by the var gene family, that are central both to the adherence of infected cells to specific human endothelial receptors and to the evasion of host immune responses raised against this adhesin. We are studying the mechanisms of gene silencing that lead to the mutually exclusive expression of a single member of the var gene family. This includes an understanding of the unique telomere biology of the parasite.

We also have a long-standing interest in elucidating the molecular basis of P. falciparum drug-resistance. In the absence of an effective vaccine, chemotherapy is the mainstay of malaria treatment. This is becomingly increasingly compromised through the development and spread of antimalarial resistance.

We are engaged in field projects with collaborators in malaria-endemic areas, including Senegal, Nigeria and Tanzania, to determine the relevance of our laboratory findings in different epidemiological settings.

Mentoring
Genetic analysis of how Duffy antigen expression level affects erythrocyte susceptibility to vivax malaria infection
Summer, 06/20/11 - 08/12/11

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R21AI168806 (DURAISINGH, MANOJ T) Nov 9, 2022 - Oct 31, 2024
    NIH
    Linking metabolite sensing and gene expression in malaria parasites
    Role: Principal Investigator
  2. R01AI167570 (GUBBELS, MARC-JAN) Jul 21, 2022 - Jun 30, 2027
    NIH
    Comparative systems biology of apicomplexan cell division
    Role: Co-Principal Investigator
  3. R21AI166478 (DURAISINGH, MANOJ T) Jul 14, 2022 - Jun 30, 2024
    NIH
    Evaluating host-directed therapeutics against blood-stage malaria parasites
    Role: Principal Investigator
  4. R01AI165755 (DURAISINGH, MANOJ T) Jul 1, 2022 - Jun 30, 2027
    NIH
    Malaria parasite determinants of host cell tropism
    Role: Principal Investigator
  5. R21AI171658 (DURAISINGH, MANOJ T) Jun 29, 2022 - Nov 30, 2024
    NIH
    Developing a barcoded malaria parasite panel to assess broadly neutralizing antibodies
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Updating...
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu.
Duraisingh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (542)
Explore
_
Co-Authors (39)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.